In the trial NCT01869166 on EGFR-CAR-T cells, 11 patients with metastatic EGFR-positive NSCLC received a single CAR-T infusion after lymphodepletion: no treatment-related serious AEs were observed, but only two partial responses and five cases of stable disease were reported, with a median PFS of 7 weeks, indicating transient antitumor activity [144]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.